Navigation Links
FDA Issues Draft Guidance on Device Changes That Warrant New Premarket Review
Date:7/26/2011

SILVER SPRING, Md., July 26, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today issued draft guidance that clarifies when changes or modifications to a previously cleared 510(k) device require a new premarket submission.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The 510(k) process is the most common review path to market for lower-risk medical devices. To legally market a device, manufacturers must submit a premarket notification or 510(k) demonstrating that the new or modified product is substantially equivalent to another legally marketed medical device.  

Manufacturers often make changes or modifications to a device after FDA clearance such as incorporating new technology or upgrading certain aspects of the device. Many changes do not require a 510(k) submission. But when the changes could significantly affect the product's safety or effectiveness or constitute a major change to the intended use of the device, another 510(k) must be submitted.

"We are making the regulatory process for medical devices less challenging by better describing our expectations," said Jeffrey Shuren, M.D., director of FDA's Center for Devices and Radiological Health. "In particular, manufacturers can continue to make innovative improvements to their devices and better plan for any updated submissions. This saves time and money."

The draft guidance clarifies the kinds of changes that trigger the need for a new submission, such as specific kinds of labeling changes, changes to the technology used in the device, changes in performance specifications, manufacturing changes, and changes in the materials used in the manufacture of the device.  

This draft guidance is one of 25 action items listed in FDA's Plan of Action for Implementation of 510(k) and Science Recommendations launched in 2011 to enhance predictability, consist
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. USPTO Issues Patent for CardioGenics Signal Amplification Technology
2. Endo Pharmaceuticals Issues Voluntary, Nationwide Recall of Two Lots of Endocet® (Oxycodone/Acetaminophen, USP) Tablets, 10 Mg /325 Mg
3. Preliminary Results of a Large Scale Study Show ConvaTec Moldable Technology™ Skin Barriers Help to Prevent and Improve Peristomal Skin Issues in Ostomy Patients
4. Health Information Technology: UC San Diego New Seminar Explores Four Critical Issues
5. FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System
6. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
7. United Kingdoms National Institute for Health and Clinical Excellence Issues Guidance on Percutaneous Tibial Nerve Stimulation for Faecal Incontinence
8. BD Issues 2010 Sustainability Report
9. MedImmune To Present Eight Abstracts on Projects Regarding Thoracic and Respiratory Issues at the Annual American Thoracic Society International Conference
10. FDA Issues Final Guidance for Liquid OTC Drug Products With Dispensing Devices
11. Dehaier Medical Chairman and CEO Issues Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab, ... (OMX:,GEN) reports today that the last patient to ... in the pivotal Phase III clinical trial,of ofatumumab ... received the last scheduled treatment., In order ...
... Company to Host Conference Call/Webcast at 8:30 a.m. ... May 28 Alfacell Corporation,(Nasdaq: ACEL ) ... from its confirmatory Phase IIIb clinical trial of ... significance for the,primary endpoint of survival in unresectable ...
Cached Medicine Technology:Genmab Announces Updates on Phase III Cancer Studies 2Genmab Announces Updates on Phase III Cancer Studies 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 2Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 4Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 5
(Date:7/9/2014)... been a sharp increase in the number of cancer ... online, interactive service that allows patients to view laboratory ... appointments, and renew prescriptions. , Over a six-year period, ... each year increased five-fold, while the number of total ... a study by Dr. David Gerber , Associate ...
(Date:7/9/2014)... of flatulence and have a reputation for being highly toxic, ... is now being being found to offer potential health benefits ... attacks and dementia. A new compound (AP39), designed and made ... future therapies, by targeting delivery of very small amounts of ... , Scientists in Exeter have already found that the ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
(Date:7/9/2014)... diseases has risen dramatically in Western societies. One frequently ... microorganisms and have fewer infections than previous generations, thereby ... by researchers at Sahlgrenska Academy, University of Gothenburg, monitored ... of the immune system in relation to allergic disease. ... the Vstra Gtaland Region, half of them on farms ...
(Date:7/8/2014)... Defense Advanced Research Projects Agency (DARPA) awarded Lawrence ... to develop an implantable neural device with the ... brain to help restore memory, DARPA officials announced ... understanding that memory is a process in which ... information, store it and retrieve it. Certain types ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... Calif., March 10 ISTA Pharmaceuticals, Inc. (Nasdaq: ... the Cowen and Company 29th Annual Health Care Conference ... 2009, in Boston, MA.ISTA,s President and Chief Executive Officer, ... the Company,s commercial and clinical progress. To access the ...
... 10 Orthocrat, Ltd. announced today that OAD ... OrthoFlow workflow solution. OrthoFlow is designed to save ... exam room to exam room, seeing large volumes of patients ... simply swipes his badge over a reader, and the images ...
... Sahlgrenska Academy, University of Gothenburg, Sweden, shows that three genes ... normally involved in several fundamental processes in the cell. This ... life and principally affect children and young people. , A ... investigated in the work presented in the thesis. This family ...
... Waterlase(TM), DIAGNOdent Laser Technology and the First Comprehensive Dental ... Area residents now have access to the latest ... all in a luxurious spa environment designed for relaxation ... and general dentist, designed her first Northern Westchester location, ...
... The Pew Charitable Trusts today announced that Susan G. Komen ... space in its D.C. headquarters, located at 901 E Street, ... Fenty, Pew has dedicated the vast majority of its building ... first "nonprofit village.""Susan G. Komen for the Cure(R) has been ...
... Health Plan Members Drop Coverage for Multiple Reasons; ... Necessary to Reduce Disenrollment and Improve Balance SheetORLANDO, ... behalf of ConnextionsHealth provides both good and bad ... properly managing member disenrollment delivers a significant, positive ...
Cached Medicine News:Health News:'Swipe Card, See Image': OAD Orthopaedics Improves Clinical Workflow with OrthoFlow 2Health News:Rearrangements of multifunctional genes cause cancer in children and young people 2Health News:High-Tech Meets Luxury at New Dental Practice: Introducing Westchester Smile Design 2Health News:Susan G. Komen for the Cure(R) Signs Lease at Pew's Nonprofit Village 2Health News:Susan G. Komen for the Cure(R) Signs Lease at Pew's Nonprofit Village 3Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 2Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 3
... generation of Urocap, features automatic ... stopping and printing. The advanced ... with superior low flow rate ... ICS nomenclature normative comparisons to ...
... Stents combine a unique polymer material that ... shape with a chemically bonded wettable solution ... is a stent that satisfies the need ... Lubri-Flex® is available in a wide variety ...
... The Pathfinder Chlamydia Culture ... reliable staining of intracellular ... reticulate bodies) in tissue ... antibody used in this ...
... a direct antigen detection system, that can use ... and monoclonal antibodies to detect RSV directly in ... and reproducibility of monoclonal antibodies with the speed ... are availalbe within 90 minutes. The Pathfinder RSV ...
Medicine Products: